CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial.

Michael L JamesJesse TroyNathaniel NowackiJordan KomisarowChrista B SwisherKristi TuckerKevin HattonMarc A BabiBradford B WorrallCharles AndrewsDaniel WooPeter G KranzChristopher LascolaMaureen MaughanDaniel T Laskowitznull null

Published in: Neurocritical care (2021)

CN-105 administration represents an excellent translational candidate for treatment of acute ICH because of its safety, dosing feasibility, favorable pharmacokinetics, and possible improvement in neurological recovery.

Keyphrases

liver failure
respiratory failure
lymph node metastasis
aortic dissection
drug induced
clinical trial
brain injury
study protocol
hepatitis b virus
phase iii
randomized controlled trial
combination therapy
subarachnoid hemorrhage
mechanical ventilation
cerebral ischemia